Funding for this research was provided by:
Received: 5 September 2021
Accepted: 5 May 2022
First Online: 18 May 2022
: Participants confirmed their voluntary consent to participate and supplied informed consent in written format. Participants confirmed their understanding that findings from the interview may be published in an anonymized format. This study was non-clinical and was for participant insight purposes only. It was exempt from Institutional Review Board (IRB) requirements per criteria listed in 45 CFR 46.101(b), category 2 for participants from the US, as it used interview procedures recorded in a way that human subjects could not be identified. IRB approval was also not required nor sought for participants from Germany, per the Association of Medical Ethics Committees (AKEK), and the study did not meet the requirements for needing ethical approval, per section 1.3 of the European Pharmaceutical Market Research Association guidelines. Respondents were not classified as vulnerable, nor would participation induce undue psychological stress or anxiety.
: Not applicable.
: LG reports grants from the US National Institute of Health, Agency for Healthcare Research and Quality, Veterans Affairs Health Services Research and Development, and an investigator-initiated grant from Rebiotix, a Ferring Company. GS has no competing interests to disclose. AM and MP are employees and stockholders of GlaxoSmithKline.